We target proteinuria because reducing proteinuria is associated with good outcomes. Turns out, people whose kidneys heal have better outcomes. #NKFClinicals
KDIGO Standard of care for Lupus Nephritis #NKFClinicals
Simplified (?) version of the above with new b-cell agents: belimumab and rituximab. #NKFClinicals
AURORA 1: voclosporin with MMF and reduced dose steroids vs placebo, MMF, reduced dose steroids.
52-week renal response: UPCR ≤0.5, eGFR ≥60, no rescue medications.
It worked. Adverse events were similar.
Now FDA approved. #NKFClinicals
NOBILITy is phase 2 trial of obinutuzumab B-cell depleting drug. Works at 2 years Improved renal end-points and bio markers. Looking forward to phase three data. #NKFClinicals
• • •
Missing some Tweet in this thread? You can try to
force a refresh
Next up is Kirsten Johansen from U of Minnesota on Emerging therapies for CKD-related anemia. She starts with a question. This is a nightmare question and will not be participating. She mocks the audience for answering wrong. #NKFClinicals
Big list of trials so you can keep the trials straight #NKFClinicals
After showing data that the HIF stabilizers raise the hemoglobin she gets to the MACE data. First up Roxa. (Emoji, my addition) #NKFClinicals
Brad is a fill in for Samir Parik
He has massive COI all over the place. Every drug. Every company. #NKFClinicals
Starts out with a case. Cr up from 0.6 to 1.2. 3500 mg of protein. Biopsy is WHO 4 and 5. She does not respond to MMF and steroids. Then does not respond to CYT. What to do?
Beware of getting on the roulette wheel of immunosuppression